BR9606769A - Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete - Google Patents
Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tableteInfo
- Publication number
- BR9606769A BR9606769A BR9606769A BR9606769A BR9606769A BR 9606769 A BR9606769 A BR 9606769A BR 9606769 A BR9606769 A BR 9606769A BR 9606769 A BR9606769 A BR 9606769A BR 9606769 A BR9606769 A BR 9606769A
- Authority
- BR
- Brazil
- Prior art keywords
- tablet
- treating
- preparing
- human
- processes
- Prior art date
Links
- 208000029433 Herpesviridae infectious disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501127.6A GB9501127D0 (en) | 1995-01-20 | 1995-01-20 | Tablet |
| PCT/GB1996/000111 WO1996022082A1 (en) | 1995-01-20 | 1996-01-19 | Valaciclovir tablets containing colloidal silicon dioxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9606769A true BR9606769A (pt) | 1997-12-30 |
Family
ID=10768317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9606769A BR9606769A (pt) | 1995-01-20 | 1996-01-19 | Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete |
Country Status (38)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| CA2243237C (en) * | 1996-01-19 | 2008-09-02 | Glaxo Group Limited | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application |
| AR017512A1 (es) * | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
| AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| BR9916361A (pt) * | 1998-12-18 | 2002-11-05 | Abbott Lab | Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia |
| GB0010446D0 (en) * | 2000-04-28 | 2000-06-14 | Glaxo Wellcome Kk | Pharmaceutical formulation |
| UA75135C2 (en) * | 2001-05-01 | 2006-03-15 | Pfizer Prod Inc | Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions |
| US7815936B2 (en) * | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| AU2002348022B2 (en) * | 2001-11-05 | 2006-06-15 | Glaxo Group Limited | Anhydrous crystal form of valaciclovir hydrochloride |
| CA2465928C (en) * | 2001-11-14 | 2010-01-19 | Teva Pharmaceutical Industries Ltd. | Synthesis and purification of valacyclovir |
| GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| EP1517678A2 (en) * | 2002-06-24 | 2005-03-30 | Ranbaxy Laboratories Limited | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
| WO2004035583A1 (en) * | 2002-10-16 | 2004-04-29 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20050059684A1 (en) * | 2002-10-16 | 2005-03-17 | Ben-Zion Dolitzky | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20040109889A1 (en) * | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
| WO2004106338A1 (en) * | 2003-05-30 | 2004-12-09 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. | Novel crystalline forms of valacyclovir hydrochloride |
| EP2014660A3 (en) * | 2003-06-02 | 2009-07-15 | Teva Pharmaceutical Industries Ltd | Novel crystalline forms of valacyclovir hydrochloride |
| US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
| HUE044822T2 (hu) | 2003-09-12 | 2019-11-28 | Amgen Inc | Cinakalcet HCl gyors feloldódású készítménye |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| EP1541133B1 (en) * | 2003-12-09 | 2005-08-10 | Helm AG | Pharmaceutical formulation of valaciclovir |
| US7344907B2 (en) * | 2004-11-19 | 2008-03-18 | International Business Machines Corporation | Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale |
| KR101116747B1 (ko) | 2004-12-06 | 2012-02-22 | 에스케이케미칼주식회사 | 안정성이 개선된 말레인산 암로디핀 약제 조성물 |
| DK1868579T3 (da) | 2005-03-07 | 2011-01-10 | Bayer Schering Pharma Ag | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer |
| ATE546451T1 (de) * | 2005-05-25 | 2012-03-15 | Lilly Co Eli | Cyclopropancarbonsäureester von acyclovir |
| EP1746098A1 (en) * | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| WO2007090595A1 (en) * | 2006-02-06 | 2007-08-16 | Fidia Pharmaceutici S.P.A. | Solid formulations of valacyclovir hydrochloride |
| JP2009536165A (ja) * | 2006-05-10 | 2009-10-08 | エボニック デグサ ゲーエムベーハー | 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用 |
| EP2037887B1 (en) * | 2006-05-31 | 2010-09-15 | Vertex Pharmaceuticals Incorporated | Oral controlled release formulations of an interleukin-1 beta converting enzyme inhibitor |
| US20090291136A1 (en) * | 2006-07-11 | 2009-11-26 | Lek Pharmaceuticals D.D. | Multiple Unit Tablets |
| US20080167325A1 (en) * | 2006-12-27 | 2008-07-10 | Bs Praveen Kumar | Valacyclovir compositions |
| US20090076039A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched valacyclovir |
| ITRM20080027A1 (it) * | 2008-01-18 | 2009-07-19 | Maria Balestrieri | Uso di aciclovir per il trattamento delle condilomatosi. |
| US20100124560A1 (en) * | 2008-11-14 | 2010-05-20 | Mcneil Ab | Multi portion intra-oral dosage form and use thereof |
| DK2407166T3 (da) * | 2009-03-13 | 2013-10-07 | Toyama Chemical Co Ltd | Tablet og granuleret pulver indeholdende 6-fluor-3-hydroxy-2-pyrazin-carboxamid |
| CH703348A1 (de) * | 2010-06-29 | 2011-12-30 | Mepha Gmbh | Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen. |
| GB2515486A (en) * | 2013-06-24 | 2014-12-31 | Kraft Foods R & D Inc | Soluble Beverage Ingredients |
| KR101497508B1 (ko) * | 2013-12-20 | 2015-03-03 | 한국유나이티드제약 주식회사 | 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| WO2020049536A1 (en) * | 2018-09-07 | 2020-03-12 | Jubilant Generics Limited | Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof |
| CN110279667B (zh) * | 2019-07-30 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种盐酸伐昔洛韦片及其制备方法 |
| EP4157221A4 (en) * | 2020-06-01 | 2024-07-24 | Shilpa Medicare Limited | RAPIDLY DISPERSABLE PHARMACEUTICAL COMPOSITION CONTAINING CAPECITABINE |
| TWI884340B (zh) * | 2020-12-01 | 2025-05-21 | 南韓商Lg化學股份有限公司 | 用於口服投予的包含1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸之複合調製劑和製備彼之方法 |
| CA3266275A1 (en) * | 2022-08-31 | 2024-03-07 | Astrazeneca Ab | PHARMACEUTICAL FORMULATION |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1259924A (en) * | 1985-03-25 | 1989-09-26 | Wallace E. Becker | Pharmaceutical tableting method |
| AP55A (en) * | 1987-08-15 | 1989-09-26 | The Wellcome Foundation Ltd | Therapeutic Acyclic Nucleosides |
| EP0349103B1 (en) * | 1988-05-04 | 1992-11-25 | Smith Kline & French Laboratories Limited | Chewable tablet |
| ATE133068T1 (de) * | 1991-01-30 | 1996-02-15 | Wellcome Found | Wasserlösliche tabletten |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| GB9317146D0 (en) * | 1993-08-18 | 1993-10-06 | Wellcome Found | Therapeutic combinations |
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
-
1995
- 1995-01-20 GB GBGB9501127.6A patent/GB9501127D0/en active Pending
-
1996
- 1996-01-19 JP JP52212696A patent/JP3350055B2/ja not_active Expired - Fee Related
- 1996-01-19 ZA ZA96448A patent/ZA96448B/xx unknown
- 1996-01-19 DK DK96900626T patent/DK0806943T3/da active
- 1996-01-19 CN CNB2003101029136A patent/CN1313081C/zh not_active Expired - Fee Related
- 1996-01-19 AP APAP/P/1997/001057A patent/AP666A/en active
- 1996-01-19 TR TR97/00657T patent/TR199700657T1/xx unknown
- 1996-01-19 DE DE69607146T patent/DE69607146T2/de not_active Expired - Lifetime
- 1996-01-19 MY MYPI96000222A patent/MY126346A/en unknown
- 1996-01-19 GE GEAP19963844A patent/GEP20022752B/en unknown
- 1996-01-19 EE EE9700352A patent/EE03336B1/xx not_active IP Right Cessation
- 1996-01-19 CZ CZ0229297A patent/CZ296514B6/cs not_active IP Right Cessation
- 1996-01-19 CA CA002210891A patent/CA2210891C/en not_active Expired - Fee Related
- 1996-01-19 EA EA199700123A patent/EA000276B1/ru not_active IP Right Cessation
- 1996-01-19 WO PCT/GB1996/000111 patent/WO1996022082A1/en not_active Ceased
- 1996-01-19 PT PT96900626T patent/PT806943E/pt unknown
- 1996-01-19 EP EP96900626A patent/EP0806943B1/en not_active Expired - Lifetime
- 1996-01-19 SK SK964-97A patent/SK282030B6/sk not_active IP Right Cessation
- 1996-01-19 US US08/875,172 patent/US5879706A/en not_active Expired - Lifetime
- 1996-01-19 BR BR9606769A patent/BR9606769A/pt not_active IP Right Cessation
- 1996-01-19 IL IL11683096A patent/IL116830A/xx not_active IP Right Cessation
- 1996-01-19 NZ NZ298846A patent/NZ298846A/en not_active IP Right Cessation
- 1996-01-19 AU AU44534/96A patent/AU710823B2/en not_active Ceased
- 1996-01-19 CN CN96192661A patent/CN1131026C/zh not_active Expired - Fee Related
- 1996-01-19 AT AT96900626T patent/ATE190483T1/de not_active IP Right Cessation
- 1996-01-19 KR KR1019970704915A patent/KR100412298B1/ko not_active Expired - Lifetime
- 1996-01-19 HU HU9801872A patent/HU226131B1/hu not_active IP Right Cessation
- 1996-01-19 RO RO97-01333A patent/RO118175B1/ro unknown
- 1996-01-19 ES ES96900626T patent/ES2145425T3/es not_active Expired - Lifetime
- 1996-01-19 UA UA97084269A patent/UA68325C2/uk unknown
- 1996-01-19 IN IN100MA1996 patent/IN181318B/en unknown
-
1997
- 1997-07-16 OA OA70052A patent/OA10500A/en unknown
- 1997-07-18 PL PL96321361A patent/PL185307B1/pl not_active IP Right Cessation
- 1997-07-18 FI FI973062A patent/FI119722B/fi not_active IP Right Cessation
- 1997-07-18 NO NO19973327A patent/NO311488B1/no not_active IP Right Cessation
- 1997-08-14 BG BG101831A patent/BG63187B1/bg unknown
-
1999
- 1999-10-28 UY UY25774A patent/UY25774A1/es unknown
- 1999-10-29 UY UY25778A patent/UY25778A1/es not_active IP Right Cessation
-
2000
- 2000-06-14 GR GR20000401364T patent/GR3033677T3/el not_active IP Right Cessation
- 2000-08-23 CY CY0000042A patent/CY2182B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9606769A (pt) | Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete | |
| IL126924A0 (en) | Antimicrobial treatment for herpes simplex virus and other infectious diseases | |
| ITMI951160A0 (it) | Chiodo endomidollare bloccato adatto in particolare per le fratture del femore | |
| EP0831873A4 (en) | COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS | |
| FI963696A7 (fi) | Geeli ihosairauksien hoitoon ja ihon desinfiointiin | |
| AU7230196A (en) | Pskh-1 ribozymes and uses in disease treatment | |
| EE03774B1 (et) | 5-O-desosaminüül-6-O-metüülerütronoliid A derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete produktide valmistamiseks | |
| FI944600A7 (fi) | Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa | |
| ZA936592B (en) | Nutrition for persons infected with human immunodeficiency virus | |
| IL102092A0 (en) | Vaccine and treatment method for human immunodeficiency virus | |
| FI955426L (fi) | Pintakäsittelytuotteet ja menetelmät niiden valmistamiseksi | |
| GB9709360D0 (en) | Methods for the treatment of herpes virus infections | |
| EE04371B1 (et) | Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena | |
| HUP9903886A3 (en) | Azacycloalcane derivatives, preparation thereof and their applications in therapy | |
| BR9607599A (pt) | Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon | |
| FI941911A7 (fi) | Kondensoidut kinolyylidihydropyridiinit, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa | |
| GB8926595D0 (en) | Pharmaceutical compositions for use in the treatment herpes simplex virus infections | |
| BR9607169A (pt) | Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas | |
| AP9100290A0 (en) | Pharmaceutical treatment | |
| BR9601193A (pt) | Vacina de múltiplos componentes e processos para preparar e administrar a vacina | |
| AU3909389A (en) | Il-1alpha derivatives and medicament for treating thrombocytopenia | |
| IL123156A0 (en) | Benzenesulphonamide derivatives their preparation and their application in therapy | |
| DK0726250T3 (da) | Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåder til deres fremstilling og deres anvendelse til | |
| FI950728A7 (fi) | 15-deoksispergualiinianalogit, menetelmä niiden valmistamiseksi ja niiden käyttö lääkinnässä | |
| PL312563A1 (en) | Pharmaceutical immunomodulating and treatment aiding preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| HJEG | Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law | ||
| FF | Decision: intention to grant | ||
| FG9A | Patent or certificate of addition granted | ||
| B17A | Notification of administrative nullity (patentee has 60 days time to reply to this notification) |
Free format text: NATURE'S PLUS FARMACEUTICAL LTDA. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE AS 16A, 17A, 18A, 19A E 20A ANUIDADES. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |